Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Saved in:
| Title: | Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. |
|---|---|
| Authors: | Long, G.V.1,2,3,4 (AUTHOR) georgina.long@sydney.edu.au, Arance, A.5 (AUTHOR), Mortier, L.6 (AUTHOR), Lorigan, P.7,8 (AUTHOR), Blank, C.9 (AUTHOR), Mohr, P.10 (AUTHOR), Schachter, J.11 (AUTHOR), Grob, J.-J.12 (AUTHOR), Lotem, M.13 (AUTHOR), Middleton, M.R.14 (AUTHOR), Neyns, B.15 (AUTHOR), Steven, N.16 (AUTHOR), Ribas, A.17 (AUTHOR), Walpole, E.18,19 (AUTHOR), Carlino, M.S.1,20 (AUTHOR), Lebbe, C.21 (AUTHOR), Sznol, M.22 (AUTHOR), Jensen, E.23 (AUTHOR), Leiby, M.A.23 (AUTHOR), Ibrahim, N.23 (AUTHOR) |
| Source: | Annals of Oncology. Feb2022, Vol. 33 Issue 2, p204-215. 12p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 154790310 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Long%2C+G%2EV%2E%22">Long, G.V.</searchLink><relatesTo>1,2,3,4</relatesTo> (AUTHOR)<i> georgina.long@sydney.edu.au</i><br /><searchLink fieldCode="AR" term="%22Arance%2C+A%2E%22">Arance, A.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mortier%2C+L%2E%22">Mortier, L.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lorigan%2C+P%2E%22">Lorigan, P.</searchLink><relatesTo>7,8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Blank%2C+C%2E%22">Blank, C.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mohr%2C+P%2E%22">Mohr, P.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schachter%2C+J%2E%22">Schachter, J.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Grob%2C+J%2E-J%2E%22">Grob, J.-J.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lotem%2C+M%2E%22">Lotem, M.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Middleton%2C+M%2ER%2E%22">Middleton, M.R.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Neyns%2C+B%2E%22">Neyns, B.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Steven%2C+N%2E%22">Steven, N.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ribas%2C+A%2E%22">Ribas, A.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Walpole%2C+E%2E%22">Walpole, E.</searchLink><relatesTo>18,19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Carlino%2C+M%2ES%2E%22">Carlino, M.S.</searchLink><relatesTo>1,20</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lebbe%2C+C%2E%22">Lebbe, C.</searchLink><relatesTo>21</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sznol%2C+M%2E%22">Sznol, M.</searchLink><relatesTo>22</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Jensen%2C+E%2E%22">Jensen, E.</searchLink><relatesTo>23</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leiby%2C+M%2EA%2E%22">Leiby, M.A.</searchLink><relatesTo>23</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ibrahim%2C+N%2E%22">Ibrahim, N.</searchLink><relatesTo>23</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Feb2022, Vol. 33 Issue 2, p204-215. 12p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=154790310 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2021.10.010 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 12 StartPage: 204 Titles: – TitleFull: Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Long, G.V. – PersonEntity: Name: NameFull: Arance, A. – PersonEntity: Name: NameFull: Mortier, L. – PersonEntity: Name: NameFull: Lorigan, P. – PersonEntity: Name: NameFull: Blank, C. – PersonEntity: Name: NameFull: Mohr, P. – PersonEntity: Name: NameFull: Schachter, J. – PersonEntity: Name: NameFull: Grob, J.-J. – PersonEntity: Name: NameFull: Lotem, M. – PersonEntity: Name: NameFull: Middleton, M.R. – PersonEntity: Name: NameFull: Neyns, B. – PersonEntity: Name: NameFull: Steven, N. – PersonEntity: Name: NameFull: Ribas, A. – PersonEntity: Name: NameFull: Walpole, E. – PersonEntity: Name: NameFull: Carlino, M.S. – PersonEntity: Name: NameFull: Lebbe, C. – PersonEntity: Name: NameFull: Sznol, M. – PersonEntity: Name: NameFull: Jensen, E. – PersonEntity: Name: NameFull: Leiby, M.A. – PersonEntity: Name: NameFull: Ibrahim, N. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: Feb2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 33 – Type: issue Value: 2 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
